Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 3Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Fluorouracil 145Gemcitabine 141Oxaliplatin 135Capecitabine 133Leucovorin 107Irinotecan 99Bevacizumab 92Cetuximab 69Cisplatin 67pembrolizumab 61Radiotherapy 60Nivolumab 41130-nm albumin-bound paclitaxel 41Sorafenib 39Docetaxel 34Albumin-Bound Paclitaxel 31Radiosurgery 28Paclitaxel 27Surgical Procedures, Operative 25regorafenib 24Erlotinib Hydrochloride 23Panitumumab 22Cyclophosphamide 21Celecoxib 20Trastuzumab 19Radiation 18Neoadjuvant Therapy 18IFL protocol 18atezolizumab 17Carboplatin 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × cabiralizumab × Gastrointestinal × Clear all
NCT04050462 2025-10-16

Nivolumab Combined With BMS-986253 in HCC Patients

NYU Langone Health

Phase 2 Terminated
13 enrolled 13 charts
Gastrointestinal

Carcinoma, Hepatocellular

NCT03599362 2021-10-19

Study of Nivolumab, Cabiralizumab, and Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Unresectable Pancreatic Cancer

NYU Langone Health

Phase 2 Terminated
7 enrolled 10 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡